Looking after the overlooked

Theratechnologies is a commercial-stage biopharmaceutical company. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV and oncology.

Most recent

October 28, 2020

Theratechnologies’ Presentation at the B. Riley Securities Liver Disease Therapeutics Day 2020

October 22, 2020

Theratechnologies To Present At Upcoming Investor Conferences On October 29 And November 10, 2020

October 16, 2020

Theratechnologies Appoints Two New Board Members

Making a difference

Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing niche therapeutic needs.

Our values


The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.


There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.


We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our commercialized products

Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is only approved in the United States. EGRIFTA® is approved in the United States, Canada and Mexico but is no longer available in the United States.